Abstract: An aqueous treating medium may include water; an acid selected from the group consisting of: HCl, HBr, HNO3, H2SO4, H2SO3, H3PO4, H3PO2, HOAc, citric acid, tartaric acid, ascorbic acid, EDTA, methanesulfonic acid, toluenesulfonic acid, and combinations thereof, wherein a concentration of the acid in the aqueous treating medium is from 0.5 M to 1.5 M; a salt, wherein a concentration of the salt in the aqueous treating medium is from greater than 0 M to 2 M; a fluoride-containing compound selected from the group consisting of: HF, NaF, NH4HF2, and combinations thereof, wherein a concentration of the fluoride-containing compound in the aqueous treating medium is from 0.026 M to 0.26 M; and silica, wherein the aqueous treating medium is saturated with silica.

Abstract: A fining package for a glass composition may include a sulfate or a sulfide in an amount from about 0.001 to about 1 mol % of the glass composition. The fining package may include a multivalent compound, such as CeO2, SnO2, or Fe2O3, in an amount from about 0.001 to about 1 mol % of the glass composition. The fining package may be sulfide-free. The fining package may be free from a reducing agent for reducing sulfate to sulfide. The fining package may be free of at least one of Cl, F, Sn, Ce, and As. The glass composition may be used to form glass tubing. The glass tubing may be used to form a pharmaceutical packaging.

Abstract: Glass-based articles that include a compresive stress layer extending from a surface of the glass-based article to a depth of compression are formed by exposing glass-based substrates to water vapor containing environments. The methods of forming the glass-based articles may include elevated pressures and/or multiple exposures to water vapor containing environments.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Glass-based articles that include a compressive stress layer extending from a surface of the glass-based article to a depth of compression are formed by exposing glass-based substrates to water vapor containing environments. The methods of forming the glass-based articles may include elevated pressures and/or multiple exposures to water vapor containing environments.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (Tg) that is greater than or equal to ?70° C. and less than or equal to ?45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10?6 cm3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to ?45° C.

Abstract: Caps for sealing assemblies for sealing glass containers and maintaining container closure integrity at ?80° C. or less are disclosed. The caps include a cap skirt having an annular body and a crimp region. The crimp region is a crimpable metal. The annular body of the cap skirt has a coefficient of thermal expansion (CTE) greater than a CTE of a metal consisting of aluminum, a stiffness greater than or equal to 2 times a stiffness of the crimp region, or both. The greater CTE, stiffness, or both of the cap skirt increase the seal pressure and contact area between the stopper and glass container when cooled to ?80° C. or less. The caps enable the sealing assemblies to maintain a helium leakage rate of the sealed glass container of less than or equal to 1.4×10?6 cm3/s at ?80° C. or less.

Abstract: A sealed pharmaceutical container including: a shoulder; a neck extending from the shoulder; a flange extending from the neck, the flange including: an underside surface extending from the neck; an outer surface extending from the underside surface, the outer surface defining an outer diameter of the flange; and an upper sealing surface extending between the outer surface and an inner surface defining an opening in the sealed pharmaceutical container, and a sealing assembly including: a stopper including a sealing portion extending over the upper sealing surface of the flange and covering the opening, and an insertion portion extending into the opening and in contact with the inner surface of the flange, the stopper having a first CTE; and a filler member encased within the stopper and having a second CTE, the second CTE being lower than the first CTE.

Abstract: A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, a flange extending from the neck, and a sealing assembly. The flange includes an underside surface extending from the neck, an outer surface extending from the underside surface, the outer surface defining an outer diameter of the flange, and an upper sealing surface extending between the outer surface and an inner surface defining an opening in the sealed pharmaceutical container. The sealing assembly includes a stopper and a metal-containing cap securing the stopper to the flange. The stopper includes a sealing portion extending over the upper sealing surface of the flange and covering the opening, and a rim extending at least partially along the outer surface of the flange.

Abstract: A sealed pharmaceutical container includes a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange includes an inclined sealing surface defining an opening in the sealed pharmaceutical container. The sealed pharmaceutical container also includes a sealing assembly including a stopper extending over the sealing surface of the flange and a cap securing the stopper to the flange. The stopper has a glass transition temperature (Tg) that is greater than or equal to ?70° C. and less than or equal to ?45° C. The sealing assembly maintains a helium leakage rate of the sealed pharmaceutical container of less than or equal to 1.4×10?6 cm3/s as the sealed pharmaceutical container is cooled to a temperature of less than or equal to ?45° C.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: A sealed pharmaceutical container comprises a flange comprising an underside surface, an outer surface extending from the underside surface, the outer surface defining an outer radius ro of the flange; and an upper surface extending between the outer surface and an inner surface defining an opening in the sealed pharmaceutical container. The upper surface comprises a sealing region extending between the opening and the outer surface and comprising a radius rsr that is less than ro. The sealed pharmaceutical container also comprises a sealing assembly comprising sealing portion in contact with the upper surface at a lower surface of the sealing portion and a cap compressing the stopper against the upper surface. After compression, the sealing portion of the stopper comprises a compressed radius rsc that is less than rsr adjacent the upper surface.

Abstract: A glass container includes a glass body comprising an external surface, an internal surface opposite the external surface, a thickness T extending between the external surface and the internal surface, and an external surface layer extending from the external surface into the thickness of the glass body, wherein the external surface layer has a porosity greater than a porosity of a remainder of the glass body extending from the external surface layer to the internal surface.

Abstract: A sealed pharmaceutical container comprises a shoulder, a neck extending from the shoulder, and a flange extending from the neck. The flange comprises an outer surface extending from the underside surface and a contact surface extending between the outer surface and an inner surface defining an opening in the sealed pharmaceutical container. The contact surface comprises an outer peripheral edge disposed proximate to the outer surface of the flange. The sealed pharmaceutical container comprises a sealing assembly comprising a stopper extending over the contact surface of the flange and covering the opening, and a cap securing the stopper to the flange. The stopper comprises a sealing surface that is secured in contact with the contact surface of the flange to form a seal between the flange and the stopper. An outer peripheral edge of the sealing surface is disposed at or radially inward of the outer peripheral edge.

Abstract: Glass compositions include titania (TiO2), lanthanum oxide (La2O3), boron oxide (B2O3), silica (SiO2) as essential components and may optionally include zirconia (ZrO2), niobia (Nb2O5), calcium oxide (CaO), barium oxide (BaO), yttria (Y2O3), zinc oxide (ZnO), gadolinium oxide (Gd2O3), gallia (Ga2O3), tungsten oxide (WO3) and other components. The glasses may be characterized by high refractive index at 587.56 nm at comparably low density at room temperature.

Abstract: Glass compositions include boron oxide (B2O3), lanthanum oxide (La2O3), titania (TiO2) and niobia (Nb2O5) as essential components and may optionally include silica (SiO2), tungsten oxide (WO3), zirconia (ZrO2), yttria (Y2O3), bismuth oxide (Bi2O3), barium oxide (BaO), TeO2 and other components. The glasses may be characterized by high refractive index at 587.56 nm at comparably low liquidus temperature.

Abstract: Glass-based articles that include a reduced Youngs modulus layer extending from a surface of the glass-based article to a depth of layer and an optional compressive stress layer extending from a surface of the glass-based article to a depth of compression are formed by exposing glass-based substrates to water vapor containing environments. The methods of forming the glass-based articles may include elevated pressures and/or multiple exposures to water vapor containing environments. The glass-based articles may be utilized in foldable or flexible electronic devices.